Evidence map›Paper›PMID 32983179›Full record

ReviewFrontiers in immunology2020

Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines.

Joana Vitte, Moïse Michel, Soraya Mezouar, Aïssatou Bailo Diallo, Asma Boumaza, Jean-Louis Mege, Benoit Desnues

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2021
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Joana VitteAix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
Moïse MichelAix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
Soraya MezouarAix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
Aïssatou Bailo DialloAix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
Asma BoumazaAix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
Jean-Louis MegeAix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
Benoit DesnuesAix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
Aix-Marseille Université · FRMéditerranée Infection Foundation · FRInstitut de Recherche pour le Développement · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rapid spread, severity, and lack of specific treatment for COVID-19 resulted in hasty drug repurposing. Conceptually, trials of antivirals were well-accepted, but twentieth century antimalarials sparked an impassioned global debate. Notwithstanding, antiviral and immunomodulatory effects of aminoquinolines have been investigated

Indexed as

ImmunomodulationAntimalarialsAntiviral AgentsBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentDrug RepositioningHumansHydroxychloroquineImmunologic FactorsPandemicsPneumonia, ViralSARS-CoV-2AntimalarialsAntiviral AgentsHydroxychloroquineImmunologic FactorschloroquineCOVID-19hydroxychloroquineimmune modulationSARS-CoV-2

Identifiers

PMID32983179
PMCPMC7484884
OpenAlexW3082453528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.